Clinical trials for Anal cancer

93 currently recruiting clinical trials
Phase 3 Anal cancer #NCT06207981 #2023-505972-32-00
Locally Advanced
Radiotherapy Radiotherapy
54 recruiting sites
Fédération Francophone de Cancérologie Digestive
Phase 3 Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer #NCT07087054 #2024-519875-24-00
Neuroendocrine tumor None
6 recruiting sites
Crinetics Pharmaceuticals Inc.
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06581432 #2023-510429-14-00
HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Boehringer Ingelheim
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST #NCT06760819 #2024-517419-62-00
Stomach Oesogastric junction Esophagus Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other HER2 Positive Locally Advanced Metastatic Metastatic Castration-resistant HER2 1
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT03767075 #2024-514238-19-00
Module 2 bras 2B, Module 3 bras 3A et 3C
Locally Advanced Metastatic Metastatic Castration-resistant EGFR FGFR MET 1 2 3 or more
Systemic Treatment-Naive
1 recruiting site
Institut d'oncologie du Vall d'Hebron
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT05384626 #2024-514266-39-00
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
AKT ATM BRAF BRCA 1/2 CDK12 CHEK 1/2 ESR FGFR HER2 HOXB13 KRAS G12C KRAS non G12C MET MSI/dMMR NRAS NTRK-1/2/3 PALB2 PIK3CA PTEN RET Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06653777 #2024-512729-10-00
Locally Advanced Metastatic Metastatic Castration-resistant FGFR 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer #NCT05732831 #2022-502645-99-00
Locally Advanced Metastatic Metastatic Castration-resistant MTAP 1 2 3 or more
Systemic Treatment-Naive
4 recruiting sites
Tango Therapeutics
Phase 2 Anal cancer #NCT04894370 #2024-516005-23-00
Other Metastatic 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Institut National du Cancer, France
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer #NCT05503797 #2024-513578-23-00
Neuroendocrine tumor Locally Advanced Metastatic BRAF 1 2 3 or more
HRAS KRAS G12C KRAS non G12C NRAS Systemic Treatment-Naive
7 recruiting sites
Fore Biotherapeutics